DiaMedica Therapeutics (DMAC) News Today → Invest in the 'Trojan Horse' of Alzheimer's Treatment (From Behind the Markets) (Ad) Free DMAC Stock Alerts $3.17 +0.16 (+5.32%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 9:40 PM | investing.comDiaMedica Therapeutics Inc (DMAC)May 13, 2024 | seekingalpha.comDiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call TranscriptMay 13, 2024 | finance.yahoo.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call TranscriptMay 8, 2024 | msn.comDMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024May 8, 2024 | finance.yahoo.comDiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial ResultsMay 3, 2024 | marketbeat.comDiaMedica Therapeutics (DMAC) Set to Announce Earnings on WednesdayDiaMedica Therapeutics (NASDAQ:DMAC) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.May 2, 2024 | finance.yahoo.comDiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024May 2, 2024 | businesswire.comDiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024May 1, 2024 | finance.yahoo.comBullish DiaMedica Therapeutics Insiders Loaded Up On US$15.7m Of StockApril 24, 2024 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Earns Buy Rating from Analysts at Craig HallumCraig Hallum began coverage on shares of DiaMedica Therapeutics in a report on Wednesday. They issued a "buy" rating and a $8.00 target price on the stock.April 24, 2024 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 3.6% DiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 3.6%April 17, 2024 | businesswire.comDiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic StrokeMarch 25, 2024 | finance.yahoo.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call TranscriptMarch 23, 2024 | investorplace.comWall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy RichMarch 22, 2024 | seekingalpha.comDiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | marketbeat.comCraig Hallum Cuts DiaMedica Therapeutics (NASDAQ:DMAC) Price Target to $8.00Craig Hallum reduced their price objective on DiaMedica Therapeutics from $11.00 to $8.00 and set a "buy" rating for the company in a research note on Thursday.March 21, 2024 | marketbeat.comDiaMedica Therapeutics' (DMAC) Outperform Rating Reiterated at OppenheimerOppenheimer reissued an "outperform" rating and issued a $6.00 target price (down previously from $7.00) on shares of DiaMedica Therapeutics in a research note on Thursday.March 20, 2024 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Announces Quarterly Earnings ResultsDiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) released its earnings results on Tuesday. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14).March 19, 2024 | investorplace.comDMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023March 19, 2024 | benzinga.comRecap: DiaMedica Therapeutics Q4 EarningsMarch 19, 2024 | businesswire.comDiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial ResultsMarch 6, 2024 | ca.finance.yahoo.comTryp Therapeutics Inc. (TRYP.CN)February 9, 2024 | benzinga.comDiaMedica Therapeutics Stock (NASDAQ:DMAC) Dividends: History, Yield and DatesFebruary 1, 2024 | marketbeat.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Significant Growth in Short InterestDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 202,000 shares, an increase of 7.0% from the December 31st total of 188,800 shares. Based on an average daily trading volume, of 50,800 shares, the short-interest ratio is presently 4.0 days.January 29, 2024 | finance.yahoo.comDiaMedica Therapeutics Announces Poster Presentation at International Stroke ConferenceJanuary 7, 2024 | finance.yahoo.comDiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 52% ownership, insiders own 37%January 3, 2024 | marketbeat.comShort Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Increases By 5.3%DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 193,100 shares, an increase of 5.3% from the November 30th total of 183,300 shares. Based on an average daily trading volume, of 52,300 shares, the days-to-cover ratio is presently 3.7 days.December 16, 2023 | marketbeat.comShort Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Declines By 24.9%DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the target of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 183,300 shares, a decrease of 24.9% from the November 15th total of 244,200 shares. Based on an average daily volume of 59,400 shares, the short-interest ratio is presently 3.1 days.December 11, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn SituationNovember 15, 2023 | finance.yahoo.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Diamedica Therapeutics (DMAC), Abivax SA Sponsored ADR (ABVX)November 14, 2023 | finance.yahoo.comQ3 2023 DiaMedica Therapeutics Inc Earnings CallNovember 14, 2023 | gurufocus.comDiaMedica Therapeutics Inc. (DMAC) Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | finance.yahoo.comDiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$20.2mNovember 13, 2023 | msn.comDiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.01November 13, 2023 | finance.yahoo.comDiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial ResultsNovember 10, 2023 | benzinga.comEarnings Outlook For DiaMedica TherapeuticsNovember 9, 2023 | finance.yahoo.comDiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023November 6, 2023 | finance.yahoo.comDiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023September 12, 2023 | finance.yahoo.comDiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology OfficerSeptember 6, 2023 | finance.yahoo.comDiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth ConferenceAugust 31, 2023 | finance.yahoo.comIs DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?August 15, 2023 | finance.yahoo.comQ2 2023 DiaMedica Therapeutics Inc Earnings CallAugust 14, 2023 | finance.yahoo.comDiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial ResultsAugust 8, 2023 | finance.yahoo.comDiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023July 18, 2023 | finance.yahoo.comDiaMedica Therapeutics to Attend the American Academy of Neurology Summer ConferenceJuly 14, 2023 | marketbeat.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Large Growth in Short InterestDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) saw a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 713,600 shares, an increase of 910.8% from the June 15th total of 70,600 shares. Currently, 4.0% of the shares of the company are short sold. Based on an average daily volume of 131,600 shares, the days-to-cover ratio is presently 5.4 days.July 6, 2023 | msn.comDiaMedica Therapeutics (DMAC) Price Target Increased by 11.11% to 8.50July 5, 2023 | msn.comThree (3) Stocks Under $10 That Insiders Are BuyingJuly 5, 2023 | insidertrades.comThree (3) Stocks Under $10 That Insiders Are Buying Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address “Dollar Will Be Worth NOTHING” -Musk (Ad)Elon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher. Click here to claim your free seat ticket now. DMAC Media Mentions By Week DMAC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DMAC News Sentiment▼1.310.55▲Average Medical News Sentiment DMAC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DMAC Articles This Week▼41▲DMAC Articles Average Week Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Coya Therapeutics News Vistagen Therapeutics News Nuvectis Pharma News FibroGen News Adagene News Immunic News Amylyx Pharmaceuticals News Abeona Therapeutics News OptiNose News Rezolute News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DMAC) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsObama’s Forever Term [exposed]Porter & CompanyGold Set to EXPLODE!Gold Safe ExchangeThe 1,000X Crypto PlaybookTrue Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
